stroke is an important cause of disability and death worldwide, with the majority of strokes occurring in older people. thrombolysis with recombinant tissue plasminogen activator (r-tpa) is the approved treatment for acute ischemic stroke. a major concern of physicians, who treat acute ischemic stroke with recombinant tissue plasminogen activator (r-tpa,) is the risk of intracerebral hemorrhage...

no abstract

background: escherichia coli (e. coli) is the most extensively used host for the production of recombinant proteins. however, most of the eukaryotic proteins are typically obtained as insoluble, misfolded inclusion bodies that need solubilization and refolding. reteplase as a highly disulfide-bonded recombinant protein is an example of difficult to express protein in e. coli. methods: in this s...

background: firoozgar comprehensive stroke center started up as the first organized care unit in the country in 2014; this study was performed to investigate quality indicators such as reduction in mortality, morbidity and hospital stay.   methods: two groups of ischemic stroke patients were compared. the first group had been admitted in general neurology ward (non-stroke unit patients) and the...

standard protocols should be established for treating eligible stroke patients with tissue plasminogen activator (tpa) (recommendation class i, level of evidence b). the iranian standard protocol of intravenous thrombolysis with recombinant tissue plasminogen activator (ivttpa) is the best possible and easy to use method for performing intravenous thrombolysis in iran. this protocol overcomes p...

Myxoma may cause systemic embolization and frequently presents as ischemic stroke. There has been debates whether it is safe to use recombinant tissue plasminogen activator (rt-PA) in patients with cardiac myxoma who are presented with ischemic stroke at emergency department. we describe a young case of atrial myxoma with initial presentation of acute cerebral infarction symptoms who was treate...

BACKGROUND Effective anticoagulation routinely precludes patients from receiving intravenous thrombolysis with recombinant tissue plasminogen activator to reverse severe symptoms of ischemic stroke. We report what we believe to be the first case of ischemic stroke successfully treated with recombinant tissue plasminogen activator after antagonizing dabigatran with the monoclonal antibody idaruc...

Hyperhomocysteinemia can cause cerebral venous thrombosis. Recombinant tissue plasminogen activator is one of the treatment options for cerebral venous thrombosis in selected cases. We present here a 7-year-old boy with homocysteinuria with stroke. MRI of brain showed cerebral venous sinus thrombosis. We successfully treated with intravenous recombinant tissue plasminogen activator. He recovere...

Low molecular size additives such as L-arginine and the redox compounds have been used both in the culturemedium and in vitro refolding to increase recombinant proteins production. Additives increase proteinrefolding and yield of active proteins by suppressing aggregate formation or enhancing refolding process.In this work, a comparative study was performed on refolding of rec...

BACKGROUND Neuroendovascular therapy is a common treatment for patients with acute ischemic stroke of the anterior circulation who fail to respond to recombinant tissue plasminogen activator. However, although most hospitals can provide recombinant tissue plasminogen activator therapy, many cannot perform neuroendovascular therapy. Thus, use of a drip-and-ship treatment-liaison system allowing ...